Helicobacter Pylori Test Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, epidemiological studies, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) 510(k) Premarket Notification Database and De Novo Classification Database for in vitro diagnostic device approvals, European Medicines Agency (EMA) medical device regulations, Centers for Disease Control and Prevention (CDC) Division of Parasitic Diseases and Malaria, World Health Organization (WHO) Global Health Observatory and International Agency for Research on Cancer (IARC) for H. pylori-related gastric cancer statistics, National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Biotechnology Information (NCBI/PubMed) for clinical validation studies, American College of Gastroenterology (ACG) clinical guidelines, European Helicobacter and Microbiota Study Group (EHMSG), Asian Pacific Helicobacter and Microbiota Research (APHMR), Infectious Diseases Society of America (IDSA), Clinical and Laboratory Standards Institute (CLSI) for diagnostic accuracy standards, OECD Health Statistics, EU Eurostat Health Database, and national health ministry reports from Japan (MHLW), China (NHC), and India (MoHFW). These sources were used to collect H. pylori infection prevalence data, diagnostic test procedure volumes, regulatory approval pathways, clinical sensitivity/specificity studies, antimicrobial resistance patterns, and market landscape analysis for immunoassays, molecular diagnostics, urea breath tests, stool antigen tests, and endoscopic biopsy methods.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Research & Development, regulatory affairs directors, and commercial chiefs from diagnostic test manufacturers, IVD companies, and OEM suppliers. The chief of gastroenterology departments, clinical laboratory directors, hospital procurement managers, and medical directors from tertiary care hospitals, reference laboratories, gastroenterology clinics, and point-of-care diagnostic facilities were the demand-side sources. Primary research verified market segmentation by test type (non-endoscopic vs. endoscopic), confirmed product development pipelines and regulatory submission timelines, and collected insights on clinical adoption patterns, reimbursement coding (CPT/HCPCS), pricing strategies, and laboratory workflow integration.

Primary Respondent Breakdown:

By Designation: C-level Executives (32%), Director Level (31%), Others (37%)

By Region: North America (32%), Europe (29%), Asia-Pacific (31%), Rest of World (8%)

Global market valuation was derived through revenue mapping and test volume analysis. The methodology included:

Identification of 40+ key diagnostic manufacturers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across immunoassays (serology/stool antigen), molecular diagnostics (PCR/NAAT), point-of-care rapid tests, urea breath test systems, and endoscopic biopsy-based methods

Analysis of reported and modeled annual revenues specific to H. pylori testing portfolios

Coverage of manufacturers representing 72-78% of global market share in 2024

Extrapolation using bottom-up (test volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations by test type (non-endoscopic: urea breath test, stool antigen test, serology; endoscopic: histology, rapid urease test, culture, PCR), technology (immunoassays, point-of-care, molecular diagnostics), and end-user (hospitals & clinics, diagnostic laboratories, others)